Hansa Biopharma AB (NASDAQ Stockholm: HNSA) announced that its drug imlifidase met the primary endpoint in a pivotal US Phase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE